Literature DB >> 16823976

Quantitative multiplexed C-reactive protein mass spectrometric immunoassay.

Urban A Kiernan1, Riccardo Addobbati, Dobrin Nedelkov, Randall W Nelson.   

Abstract

Reported in this work is the development and application of a high sensitivity mass spectrometric immunoassay for the quantitative analysis of C-reactive protein from human plasma. Multiplexed affinity retrieval devices and methodology were developed to simultaneously target retinol binding protein, C-reactive protein, serum amyloid P component, as well as an added exogenous internal reference standard (staphylococcal enterotoxin B) for subsequent MALDI-TOF MS analysis. This approach allows for semiquantitative analysis of both retinol binding protein and serum amyloid P component while performing absolute quantitative measurements of C-reactive protein. The ability to qualitatively differentiate between all three human proteins and their associated variants is also maintained. Standard curve, QC, and human plasma samples were analyzed in a high throughput manner, which performed with a CV < 15%. The resultant human plasma sample C-reactive protein quantitative measurements were then compared to those achieved with a high sensitivity latex immunoturbidimetric assay.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16823976     DOI: 10.1021/pr0601133

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  18 in total

1.  Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics.

Authors:  Henrik Ryberg; Jiyan An; Samuel Darko; Jonathan Llyle Lustgarten; Matt Jaffa; Vanathi Gopalakrishnan; David Lacomis; Merit Cudkowicz; Robert Bowser
Journal:  Muscle Nerve       Date:  2010-07       Impact factor: 3.217

Review 2.  Mass spectrometric immunoassay revisited.

Authors:  Randall W Nelson; Chad R Borges
Journal:  J Am Soc Mass Spectrom       Date:  2011-03-08       Impact factor: 3.109

Review 3.  Replacing immunoassays with tryptic digestion-peptide immunoaffinity enrichment and LC-MS/MS.

Authors:  Jessica O Becker; Andrew N Hoofnagle
Journal:  Bioanalysis       Date:  2012-02       Impact factor: 2.681

Review 4.  Quantitative matrix-assisted laser desorption/ionization mass spectrometry.

Authors:  Mark W Duncan; Heinrich Roder; Stephen W Hunsucker
Journal:  Brief Funct Genomic Proteomic       Date:  2008-09

5.  Population studies of intact vitamin D binding protein by affinity capture ESI-TOF-MS.

Authors:  Chad R Borges; Jason W Jarvis; Paul E Oran; Stephen P Rogers; Randall W Nelson
Journal:  J Biomol Tech       Date:  2008-07

6.  Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms.

Authors:  Olgica Trenchevska; Matthew R Schaab; Randall W Nelson; Dobrin Nedelkov
Journal:  Methods       Date:  2015-03-07       Impact factor: 3.608

7.  MALDI-target integrated platform for affinity-captured protein digestion.

Authors:  Asilah Ahmad-Tajudin; Belinda Adler; Simon Ekström; György Marko-Varga; Johan Malm; Hans Lilja; Thomas Laurell
Journal:  Anal Chim Acta       Date:  2013-09-11       Impact factor: 6.558

8.  Possibilities and pitfalls in quantifying the extent of cysteine sulfenic acid modification of specific proteins within complex biofluids.

Authors:  Douglas S Rehder; Chad R Borges
Journal:  BMC Biochem       Date:  2010-07-01       Impact factor: 4.059

9.  Glycosylation status of vitamin D binding protein in cancer patients.

Authors:  Douglas S Rehder; Randall W Nelson; Chad R Borges
Journal:  Protein Sci       Date:  2009-10       Impact factor: 6.725

Review 10.  Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes.

Authors:  Hussein Yassine; Chad R Borges; Matthew R Schaab; Dean Billheimer; Craig Stump; Peter Reaven; Serrine S Lau; Randall Nelson
Journal:  Proteomics Clin Appl       Date:  2013-07-09       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.